title: Daily self-administered subcutaneous erythropoietin: benefits in haemodialysis patients.
authors.affiliation: Department of Nephrology, University Hospital, Nîmes, France.
authors.forename: C
authors.initials: C
authors.lastname: Granolleras
authors.forename: B
authors.initials: B
authors.lastname: Branger
authors.forename: G
authors.initials: G
authors.lastname: Deschodt
authors.forename: S
authors.initials: S
authors.lastname: Shaldon
authors.forename: B
authors.initials: B
authors.lastname: Nonnast-Daniel
authors.forename: M
authors.initials: M
authors.lastname: Pollok
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000209:etiology / Q000628:therapy*; D000906:Antibodies / Q000032:analysis; D004921:Erythropoietin / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D005260:Female; D006400:Hematocrit; D006801:Humans; D007279:Injections, Subcutaneous; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D006435:Renal Dialysis / Q000009:adverse effects*; D012646:Self Administration
chemical_list: D000906:Antibodies; D011994:Recombinant Proteins; D004921:Erythropoietin